Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin. - Wikidata - wikimedia - TriplyDB

Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin.

Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin.

http://www.wikidata.org/entity/Q42978398

about

Hepatitis C genotype 6: A concise review and response-guided therapy proposal Current status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6 Hepatitis C virus genotype 6: virology, epidemiology, genetic variation and clinical implication Diagnosis, management, and treatment of hepatitis C: an update Risk factors, genotype 6 prevalence, and clinical characteristics of chronic hepatitis C in Southeast Asian Americans.Meta-analysis: superior treatment response in Asian patients with hepatitis C virus genotype 6 versus genotype 1 with pegylated interferon and ribavirin Efficacy and safety of pegylated interferon plus ribavirin therapy for chronic hepatitis C genotype 6: a meta-analysis 24 versus 48 Weeks of Peginterferon Plus Ribavirin in Hepatitis C Virus Genotype 6 Chronically Infected Patients with a Rapid Virological Response: A Non-Inferiority Randomized Controlled Trial Epidemiology and treatment of hepatitis C genotypes 5 and 6 SASLT practice guidelines: management of hepatitis C virus infection.Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs.Clinical Characteristics and Treatment Outcome of Peginterferon Plus Ribavirin in Patients Infected with Genotype 6 Hepatitis C Virus in Korea: A Multicenter Study.Current therapies for chronic hepatitis C.Antiviral therapy: why does it fail in HCV-related chronic hepatitis?Systematic review: epidemiology of hepatitis C genotype 6 and its management.Systematic review: Asian patients with chronic hepatitis C infection.Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6.APASL consensus statements and management algorithms for hepatitis C virus infection.Meta-analysis of patients with hepatitis C virus genotype 6: 48 weeks with pegylated interferon and ribavirin is superior to 24 weeks.Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin.Response-guided therapy for patients with hepatitis C virus genotype 6 infection: a pilot study.Twenty-four weeks of pegylated interferon plus ribavirin effectively treat patients with HCV genotype 6a.KASL clinical practice guidelines: management of hepatitis C.

P2860

Q22305417-BE0EEE27-7964-4CD1-912D-5AEEDDF2980A Q26828972-E0E027C4-8B0A-4A74-AC04-AC33F0EBD1CB Q27024231-03AA1536-0CBC-4F77-9DB1-11301A1889EE Q29619682-5F45BF4F-BDB7-49A7-B920-72B0D5BFA606 Q33977173-CB705FC7-B09A-4B18-BA42-3B59D8B1D0A2 Q35153869-740C2599-2C29-41BD-AEAB-6959237527E0 Q35194590-13B7EC31-D266-4E20-AD1F-A090276210AE Q35824222-FE980C5D-666D-445E-970D-EA8B427E0DA8 Q36534673-5EAF561A-BB39-4681-B52F-7E7D3E9E395B Q37019765-8640C1C5-9EA3-4986-A85D-7768FAAD4768 Q37582545-A580733B-AC6C-4B66-9463-3F159E2272B9 Q37696052-05A85DA3-C03E-4B45-BF7D-1138BCD6B755 Q37823576-D4D3DA0F-21CC-445F-85FB-84139C5BB6EB Q37879193-57F79B17-D695-491A-90B2-E58DC8690BBC Q37882006-39244F5A-40DB-4970-826B-B56D16E39874 Q38096012-713F9196-E5C4-49D9-A997-E116FEFBF43F Q38164114-C4FADA15-EA56-4D59-87E3-82500CE38F56 Q38552131-A2C2E3B1-D236-4A84-A9B3-5EDEA37785D1 Q41556755-95AD3298-7008-4306-8B2E-19AD263689DC Q42382462-1B90A514-C647-446C-A3AF-C19C55F0D85F Q42980225-DD51D320-D889-4FD1-BAD3-3F5791FAD0DD Q43001742-69F8B86D-0D4D-44C0-9B36-5C3DCFD32A6C Q51836024-FE43D4A9-E1F7-4C61-9BCF-BB67663678BC

P2860

Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin.

http://www.wikidata.org/entity/Q42978398

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Higher rate of sustained virol ...... peginterferon plus ribavirin.

@en

Higher rate of sustained virol ...... peginterferon plus ribavirin.

@nl

type

label

Higher rate of sustained virol ...... peginterferon plus ribavirin.

@en

Higher rate of sustained virol ...... peginterferon plus ribavirin.

@nl

prefLabel

Higher rate of sustained virol ...... peginterferon plus ribavirin.

@en

Higher rate of sustained virol ...... peginterferon plus ribavirin.

@nl

P1433

Q42978398-5E76F1EE-BF61-491B-BB7C-1C9CDE4320B9

P1476

Q42978398-884B9A46-1C93-4647-B0CD-7DAC47741CB2

P2093

Q42978398-23AD80C3-3D1B-429B-AFF7-98A278C642CA

Q42978398-2BCC33A8-5052-4E4A-A537-F201564DD6EE

Q42978398-455D3369-62C0-467A-8A0B-5B37B4BB19CC

Q42978398-92EB897C-A383-4672-933F-1C6E3626272C

Q42978398-B0BF0BD7-0326-4857-9F86-5DF79329C879

Q42978398-DD21A5EB-67C2-4F47-8D89-A9AA52E3664C

P2860

Q42978398-0D47828C-7B72-4FE6-B8CB-57B89FCE48FC

Q42978398-11542033-46B3-46FA-A2FA-394BFF207951

Q42978398-1B0FD241-49C9-40DB-9297-AE63ECBDE293

Q42978398-3E9F4851-22FC-462F-9A64-6C334DEC75C8

Q42978398-424ECC23-7FA0-440E-98FE-CFB25203E280

Q42978398-4F96827D-C7F0-4F44-849E-4AAA502834B7

Q42978398-5254BDB0-806C-4C78-A38D-5DC5C5C047EA

Q42978398-58A0EC2D-0D20-4523-83D4-5D8D6635D6B7

Q42978398-5BFF71C5-0210-48BD-B164-E6016E9B51C0

Q42978398-7EFA1D5A-6677-46A3-ABFC-5708F1CBC57A

P304

Q42978398-671AD72E-F766-4EFF-A342-DA35D1D9E302

P31

Q42978398-74AC9716-8F7D-4979-83B7-E05BA36E5FC3

P356

Q42978398-FD887B81-33C9-477E-9749-64D9AD0D21C2

P407

Q42978398-662BD727-D952-4FF5-BBA1-1AFF90CD8FE8

P433

Q42978398-0D526A48-25E3-4C3E-B6DC-A296CB560B24

P478

Q42978398-47F1E5E6-8E85-4711-A0CA-50F9B0533236

P577

Q42978398-C63C4712-B02B-4B0F-BCB4-937698D11741

P698

Q42978398-90FD17E0-EACA-4FDE-B5EF-8CEB5A945134

P921

Q42978398-047E7B43-835F-43B4-8243-0A902D5CF5D2

P356

J.1572-0241.2008.01793.X

P1433

The American Journal of Gastroenterology

P1476

Higher rate of sustained virol ...... peginterferon plus ribavirin.

@en

P2093

Emmet B Keeffe

http://www.w3.org/2001/XMLSchema#string

Gloria Nguyen

http://www.w3.org/2001/XMLSchema#string

Huy N Trinh

http://www.w3.org/2001/XMLSchema#string

Khoa D Lam

http://www.w3.org/2001/XMLSchema#string

Mindie H Nguyen

http://www.w3.org/2001/XMLSchema#string

Ruel Garcia

http://www.w3.org/2001/XMLSchema#string

P2860

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

Introduction to therapy of hepatitis C.

Treatment of patients with hepatitis C and normal serum aminotransferase levels.

Chronic hepatitis C: genotypes 4 to 9.

Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6.

African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians.

Complete coding sequence of hepatitis C virus genotype 6a.

P304

1131-1135

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1572-0241.2008.01793.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P577

2008-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18477343

http://www.w3.org/2001/XMLSchema#string

P921